Three patients with polymyositis refractory to conventional steroid and immunosuppressive treatment, but responsive to cyclosporin A, are described. In a fourth patient cyclosporin A was used as a first line drug in combination with steroids in the treatment of lifethreatening dermatomyositis. Cyclosporin A in the management of polymyositis/dermatomyositis requires formal assessment of its costs and benefits compared with conventional treatments.
Polymyositis is an inflammatory disease of muscle of uncertain aetiology, characterised by muscle weakness and often accompanied by pain, tenderness and wasting. Treatment with corticosteroids and, sometimes, with immunosuppressive agents (for example, azathioprine, methotrexate, or cyclophosphamide) is moderately effective in many cases.' Not all patients, however, respond well to this treatment. Various other therapies have therefore been tried, including anti-lymphocyte globulin, plasma exchange, and total body irradiation, but with variable success. '2 Cyclosporin A is an immunosuppressive agent which is well-established in the transplantation oforgans including kidney, liver and bone marrow. It acts by inhibiting the production of interleukin 2 
